Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir
Phase 3 Clinical Data Presented at The International Liver Congress of the
European Association for the Study of the Liver (EASL)
NEW BRUNSWICK, N.J., May 2, 2013
NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ --Janssen R&D Ireland (Janssen)
and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for
investors and other interested parties on Friday, May 3, at approximately 8:30
a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at
The International Liver Congress of the European Associationfor the Study of
the Liver (EASL).
A pre-recorded webcast featuring management from Janssen will provide an
overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the
investigational protease inhibitor simeprevir (TMC435) administered once daily
in combination with pegylated interferon and ribavirin in treatment-naive
genotype 1 chronic hepatitis C patients.
The webcast/podcast can be accessed by visiting the Johnson & Johnson website
at www.investor.jnj.com and clicking on "Webcasts/Presentations."
SOURCE Johnson & Johnson
Contact: Press: Al Wasilewski, (732) 524-1130, Ernie Knewitz, (732) 524-6623,
Investor: Lesley Fishman, (732) 524-3922, Lisa Romanko, (732) 524-2034
Press spacebar to pause and continue. Press esc to stop.